Limits...
First trimester screening for trisomy 21 in gestational week 8-10 by ADAM12-S as a maternal serum marker.

Tørring N, Ball S, Wright D, Sarkissian G, Guitton M, Darbouret B - Reprod. Biol. Endocrinol. (2010)

Bottom Line: Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and with log MoM free beta hCG (r = 0.21, P < 0.001).The use of ADAM12-S along with biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine screening using PAPP-A and free β-hCG with or without nuchal translucency.The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational weeks 8-11.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Biochemistry, Aarhus University Hospital-Skejby, Aarhus, Denmark. nto@ki.au.dk

ABSTRACT

Background: A disintegrin and metalloprotease 12 (ADAM12-S) has previously been reported to be significantly reduced in maternal serum from women with fetal aneuploidy early in the first trimester and to significantly improve the quality of risk assessment for fetal trisomy 21 in prenatal screening. The aim of this study was to determine whether ADAM12-S is a useful serum marker for fetal trisomy 21 using the mixture model.

Method: In this case control study ADAM12-S was measured by KRYPTOR ADAM12-S immunoassay in maternal serum from gestational weeks 8 to 11 in 46 samples of fetal trisomy 21 and in 645 controls. Comparison of sensitivity and specificity of first trimester screening for fetal trisomy 21 with or without ADAM12-S included in the risk assessment using the mixture model.

Results: The concentration of ADAM12-S increased from week 8 to 11 and was negatively correlated with maternal weight. Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and with log MoM free beta hCG (r = 0.21, P < 0.001). The median ADAM12-S MoM in cases of fetal trisomy 21 in gestational week 8 was 0.66 increasing to approx. 0.9 MoM in week 9 and 10. The use of ADAM12-S along with biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine screening using PAPP-A and free β-hCG with or without nuchal translucency.

Conclusion: The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational weeks 8-11. However, including ADAM12-S in the routine risk does not improve the performance of first trimester screening for fetal trisomy 21.

Show MeSH

Related in: MedlinePlus

ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from 645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2984461&req=5

Figure 1: ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from 645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels respectively.

Mentions: In the controls the median concentration (μg/l) of ADAM12-S increased throughout the three weeks. Figure 1 shows the relationship between ADAM12-S and gestational age (top panel) and ADAM12-S and maternal weight (bottom panel). Multiple regression analysis showed significant effects (P < 0.001) on the concentration of ADAM12-S from both gestational age and maternal weight and the fitted relationship from the multiple regression model is superimposed on the plots in Figure 1. The median MoM values for ADAM12-S, PAPP-A and free beta-hCG at 8 to 11 weeks gestation and for maternal weight show an adequate model fit in each case (Figure 2).


First trimester screening for trisomy 21 in gestational week 8-10 by ADAM12-S as a maternal serum marker.

Tørring N, Ball S, Wright D, Sarkissian G, Guitton M, Darbouret B - Reprod. Biol. Endocrinol. (2010)

ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from 645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2984461&req=5

Figure 1: ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from 645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels respectively.
Mentions: In the controls the median concentration (μg/l) of ADAM12-S increased throughout the three weeks. Figure 1 shows the relationship between ADAM12-S and gestational age (top panel) and ADAM12-S and maternal weight (bottom panel). Multiple regression analysis showed significant effects (P < 0.001) on the concentration of ADAM12-S from both gestational age and maternal weight and the fitted relationship from the multiple regression model is superimposed on the plots in Figure 1. The median MoM values for ADAM12-S, PAPP-A and free beta-hCG at 8 to 11 weeks gestation and for maternal weight show an adequate model fit in each case (Figure 2).

Bottom Line: Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and with log MoM free beta hCG (r = 0.21, P < 0.001).The use of ADAM12-S along with biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine screening using PAPP-A and free β-hCG with or without nuchal translucency.The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational weeks 8-11.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Biochemistry, Aarhus University Hospital-Skejby, Aarhus, Denmark. nto@ki.au.dk

ABSTRACT

Background: A disintegrin and metalloprotease 12 (ADAM12-S) has previously been reported to be significantly reduced in maternal serum from women with fetal aneuploidy early in the first trimester and to significantly improve the quality of risk assessment for fetal trisomy 21 in prenatal screening. The aim of this study was to determine whether ADAM12-S is a useful serum marker for fetal trisomy 21 using the mixture model.

Method: In this case control study ADAM12-S was measured by KRYPTOR ADAM12-S immunoassay in maternal serum from gestational weeks 8 to 11 in 46 samples of fetal trisomy 21 and in 645 controls. Comparison of sensitivity and specificity of first trimester screening for fetal trisomy 21 with or without ADAM12-S included in the risk assessment using the mixture model.

Results: The concentration of ADAM12-S increased from week 8 to 11 and was negatively correlated with maternal weight. Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and with log MoM free beta hCG (r = 0.21, P < 0.001). The median ADAM12-S MoM in cases of fetal trisomy 21 in gestational week 8 was 0.66 increasing to approx. 0.9 MoM in week 9 and 10. The use of ADAM12-S along with biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine screening using PAPP-A and free β-hCG with or without nuchal translucency.

Conclusion: The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational weeks 8-11. However, including ADAM12-S in the routine risk does not improve the performance of first trimester screening for fetal trisomy 21.

Show MeSH
Related in: MedlinePlus